CONTINUE TO SITE
OR WAIT 15 SECS
Eisai Co. has announced the launch of Pariet® S”(pharmaceutical requiring guidance), which is highly
Singapore-based biopharmaceutical company Specialised Therapeutics (ST) has announced the Australian registrat
Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Adalvo Limited in
RevolKa Ltd., a venture-backed biotech company providing a cutting-edge artificial intelligence (AI)-driven pr
Administered through the National Health and Medical Research Council’s (NHMRC) Clinical Trials and
Rznomics Inc., a South Korea-based biopharmaceutical startup specialising in RNA-based therapeutics, has
Olympus, a Japan-headquartered medical technology company, has announced the US FDA 510(k) clearance of its EZ
United Imaging and HKSH Medical Group have announced the signing of a Memorandum of Understanding (MoU), marki
Japan-headquartered Fujifilm Corporation's Life Sciences Group companies, a portfolio of businesses offering p
Taiwan headquartered Bora Biologics, a leading contract development and manufacturing organization (CDMO)
APAC'S ALLIANCE-DRIVEN BIOTECH BOOM
Partnerships are a cornerstone of the biotech innovation process. COVID-19 acted as a catalyst, accelerating collaboration across the sector and prompting partnerships between established players for the first time. Since then, biotech alliances have become more diverse, frequent, and strategically important, especially in the Asia-Pacific (APAC) region. Biotech partnerships of APAC differ in a variety of ways from most global collaborations, primarily due to the unique geopolitical and socio-economic landscape of the region. The region has innovation hubs like Japan and South Korea as well as large, high-growth markets such as China and India. As China rapidly scales its biopharma capabilities, it is becoming both a key market and an innovator. This transformation has redefined regional deal-making, shifting the focus from technology transfer to co-development, shared commercialisation, and strategic alignment. APAC biotech deals are no longer early-stage R&D plays, they are beginning to span the full lifecycle, from bench to bedside, including commercialisation milestones. Let’s explore further the APAC's wave of regional biotech partnerships during the first five months of this calendar year ie. from January to May 2025.
POLYMER REACTION ENGINEERING XII
ECI
eci@informz.net https://engconf.us/conferences/chemical-engineering/polymer-reaction-engineering-xii/Clearwater
4th In Vivo Cell Engineering G Gene Editing Summit
Hanson Wade
info@hansonwade.com https://in-vivo-engineering.com/Boston
